HOUSTON, Dec. 3, 2019 /PRNewswire/ -- Medical device
innovation company Soliton, Inc. (Nasdaq: SOLY) today announced
that it has engaged Tailfin, an Atlanta based brand and marketing firm, to
help develop brand strategy and marketing and sales materials to
help power the launch of Soliton's Rapid Acoustic Pulse
("RAP") device for tattoo removal. RAP is a novel and proprietary
platform technology licensed from The University of Texas on behalf of the MD Anderson
Cancer Center. Tailfin, a firm with nearly two decades of
experience in bringing medical device brands to market, will help
shape positioning and messaging for the new technology launch.
"Our partnership with Tailfin is an important step in the
commercialization of our innovative RAP device – a device we
believe may revolutionize tattoo removal. Tailfin is an ideal
partner to help us build the brand around this technology, with
engaging, effective and informational brand storytelling that will
clearly articulate the advantages our new technology delivers,"
says Dr. Chris Capelli, Soliton
President, CEO and co-founder. "We are excited to reveal our
pointed and powerful marketing strategy which we anticipate will
drive physician and consumer awareness and fuel sustainable growth
we believe will support long-term shareholder value."
Join our more than 200K fans here
to follow the Company: https://soly-investors.com
With work already well underway, the Soliton and Tailfin teams
look to have initial brand elements ready in Q1 2020 with planned
enhancements scheduled to roll out in the months to follow.
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton is investigating potential additional capabilities of the
RAP technology in clinical and preclinical testing, including the
potential to improve the appearance of cellulite by creating
mechanical stress at the cellular level and inducing significant
collagen growth and the potential to treat keloid and hypertrophic
scars by targeting the stiffened environment in the intracellular
matrix.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability to successfully
market and launch the Soliton RAP device, and the timing of the
planned enhancements to the RAP device in 2020. These
statements relate to future events, future expectations, plans and
prospects. Although Soliton believes that the expectations
reflected in such forward-looking statements are reasonable as of
the date made, expectations may prove to have been materially
different from the results expressed or implied by such
forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under the heading "Item 1A. Risk Factors" in the Form
10-K for year ended December 31, 2018
we filed with the SEC and updated from time to time in our Form
10-Q filings and in our other public filings with the SEC. Any
forward-looking statements contained in this release speak only as
of its date. Soliton undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-initiates-significant-step-towards-commercialization-300967766.html
SOURCE Soliton, Inc.